EP0660844A1 - Isolierte nukleotid-sequenzen zum nachweis von neisseria gonorrhoeae - Google Patents

Isolierte nukleotid-sequenzen zum nachweis von neisseria gonorrhoeae

Info

Publication number
EP0660844A1
EP0660844A1 EP93921591A EP93921591A EP0660844A1 EP 0660844 A1 EP0660844 A1 EP 0660844A1 EP 93921591 A EP93921591 A EP 93921591A EP 93921591 A EP93921591 A EP 93921591A EP 0660844 A1 EP0660844 A1 EP 0660844A1
Authority
EP
European Patent Office
Prior art keywords
seq
sequence
probe
assay
sdsp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP93921591A
Other languages
English (en)
French (fr)
Other versions
EP0660844B1 (de
EP0660844A4 (de
Inventor
Rich Chmelo
Lisa Foltz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics Corp
Original Assignee
Boehringer Mannheim Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Corp filed Critical Boehringer Mannheim Corp
Publication of EP0660844A1 publication Critical patent/EP0660844A1/de
Publication of EP0660844A4 publication Critical patent/EP0660844A4/de
Application granted granted Critical
Publication of EP0660844B1 publication Critical patent/EP0660844B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • This invention relates to the field of clinical analysis. More specifically, it relates to analytical methods and apparatus which utilize improvements on the well known strand displacement assay. Additionally, the invention relates to nucleic acid sequences which are useful in assays for Neisseria gonorrhoeae using the strand displacement assay methodology, as well as in other nucleic acid probe assays.
  • nucleic acid molecules DNA and RNA
  • DNA and RNA can and do hybridize to complementary strands of nucleic acids, thereby forming double stranded molecules.
  • the principals of nucleic acid hybridization is built upon two deceptively simple rules. All nucleic acid molecules consist of four nucleotide bases. DNA contains bases “A”, “T” , “C” and “G”, whereas RNA contains "A”, * * U” , "C*- and "G” .
  • microorganisms "X" contains unique DNA sequence: 5'-AAACCGGCC-3' it is theoretically possible to identify the microorganism by making the unique sequence accessible and contacting it by its complement:
  • the complement contains a label, i.e., some "marker ** it will be possible to note that hybridization has occurred. It is this principle that is the core of all nucleic acid determination assays.
  • the strand displacement assay is generally described in a series of U.S. Patents, i.e. U.S. Patent Nos. 4,629,689 (Diamond et al.), 4,725,536 (Fritsch et al.), 4,725,537 (Fritsch et al.), 4,735,897 (Vary et al.), 4,752,566 (Collins et al.), 4,766,062 (Diamond et al.), 4,766,064 (Williams et al. (, 4,767,699 (Vary et al.), 4,795,701 (Vary) , 4,818,680 (Collins et al. ) .
  • a test sample believed to contain a nucleic acid sequence of interests with a hyrid complex of two nucleic acid sequences of differing lengths.
  • the longer sequence is referred to as the binding probe, and is complementary to the nucleic acid sequence of interest.
  • a shorter sequence referred to as the signal probe, is hybridized to only a portion of the binding probe. That portion of the binding probe which is not hybridized to signal probe is referred to as the initial binding region.
  • TTGGCCGG GGCC wherein "TTGGCCGG” is the binding probe, "TTGG” is the initial binding region, and "GGCC” is the signal probe.
  • the binding probe binds to the target sequence via the initial binding region, or "IBR”.
  • the binding probe continues to hybridize to the target molecule, because it is longer than the signal probe, and complexes which include longer molecules are more stable. Nucleic acids do not form stable triplex complexes, however, and thus the signal probe is "displaced”. When the signal probe is labelled, this displacement can be measured.
  • the strand displacement assay is useful, but is not without its problems, not the least of which is sensitivity.
  • Pathological conditions are known, e.g., where a difference between normality and abnormality rests in a single nucleotide base difference.
  • Sickle cell anemia is simply the most well known example of a pathological condition identified by this type of point mutation.
  • There are other analytes where determination of a single nucleotide base is important, or where differences between various microorganisms is slight. Identification and determination in such contexts requires levels of sensitivity and specificity not previously obtainable with strand displacement assays.
  • Neisseria cronorrhoeae the causative agent of a sexually .transmitted disease, with an estimated two million reported cases per year.
  • Examples of the patent literature regarding N. cronorrhoeae specific nucleic acid probes include U.S. Patent Nos. 4,900,659 to Lo et al, and 5,047,523 and 5,099,011 both to Woods et al. These patents deal with DNA:DNA hybridization, and disclose probes which, while useful, are simply not very specific.
  • probes which vary in only a single base pair from comparable sequences of different species of Neisseria can be used to identify N. qonorrhoeae.
  • Such probes are another feature of the invention as described herein.
  • Figure 1 presents initial binding studies using N. qonorrhoeae specific hybrid complexes.
  • Figure 2 shows results of studies identifying single base pair mismatching.
  • Figure 6 demonstrates the sensitivity of the assay.
  • Figure 7 shows specificity of the assay for extracted RNA.
  • Figure 8 also shows specificity for extracted RNA.
  • Figure 9 depicts results secured with samples of lysed bacteria.
  • Figure 10 shows results of studies on sickle cell anemia DNA.
  • Figure 11 presents data using a solid phase based assay.
  • Figure 12 also shows displacement assays using beads.
  • Figure 13 is a diagram of a typical strip format assay.
  • Figure 14 shows results obtained using the strip format.
  • Figure 15 shows results obtained in a solid phase kinetics assay.
  • Figure 16 also shows results from a solid phase kinetics assay.
  • Figure 17 shows results of a solid phase assay using crude rRNA extracts.
  • Figure 18 presents a model for an on strip capture assay.
  • Figure 19 shows results secured using an on strip capture assay.
  • nucleic acids 1262-1281 was non-homologous: AGCCGCGAGGCGGAGCCA 1 (SEQ ID NO: 1)
  • AGCCGCG G CGGAGCCA 2 (SEQ ID NO: 2)
  • CAGTCTCCCTCCACCTTAAGGTGCACA (SEQ ID NO: 4) ; TGACTGCAAGTACAGGCTTTCGCACCC (SEQ ID NO: 5) ; CAACGGTAGTAAGCCAAACCCGTGAGA (SEQ ID NO: 6) .
  • base 674 is "C”, as compared to "T” in the two other Neisseria species.
  • base 763 is "A” as compared to the other two
  • base 1138 is "C” as compared to "T” for the other two strains. Sequences complementary to these are also useful.
  • N. qonorrhoeae For the chosen sequence to be useful, they must identify N. qonorrhoeae as generally as possible, while not hybridizing to non-N. qonorrhoeae material.
  • probes were prepared therefrom via 5'- end labelling. Oligonucleotides corresponding to SEQ ID NOS: 4, 5 and 6 (1.0 ul, approx. 2.46 pmol) were mixed with 13.09 ul distilled H 2 0, 2.0 ul of buffer, 3.66 ul of y- 32 P-ATP, and 0.25 ul T 4 polynucleotide kinase. The mixture was incubated at 37°C for 30 minutes, after which 2.5 ul of 0.1 M EDTA, at pH 8.0 was added. The mixture was kept on ice, at 4°C, until needed.
  • Example 3 Initial experiments were carried out based upon the non-homologous sequence described by SEQ ID NO: 1. To perform these, a hybrid complex was prepared which contained, as the long binding probe an 80 nucleotide sequence. This long sequence was complementary to SEQ ID NO: 1, and began 49 bases from the 5' end of SEQ ID NO: 1. A signal probe was hybridized over the last 25 bases of the 3' end:
  • GAGGCGGAGCCAATCTCACAAAACC SEQ ID NO: 7
  • the 25 nucleotide probe was labelled in the manner described supra.
  • Displacement assays were carried out in the manner described by Diamond et al., U.S. Patent No. 4,766,022 and Collins et al., EPA 167238. For completeness, however, the protocols are set forth. First, to hybridize the two components described supra, the following components were combined, in a 1.5 ml microfuge tube:
  • Final volume was 25 ul, with a final salt concentration of 1.24xSSC and 10% PEG.
  • the mixture was incubated at 37°C for 60 minutes, and then kept on ice or at 4°C until needed.
  • To assay for the analyte 1.0 ul of hybrid complex was combined with 3 ul of distilled water, 4.0 ul of 25% PEG, 1.0 ul 20xSSC, and 1.0 ul of sample. The mixture was incubated at 50°C, for anywhere from 1-4 hours. Displacement of signal probe was determined via electrophoresis.
  • the mixture was run through a 20% non- denaturing polyacrylamide gel (30% acrylamide solution: 66.6 ml, water: 21.3 ml; 3% ammonium persulfate: 2.1 ml; lOxTBE: 10.0 ml) , filtered through a 0.45 um sterile filter unit. A total of 44 ul of TEMED was added, and the mixture was allowed to set. Sample was added (1500 volts, 2 hours, buffer lxTBE; loading buffer: 30% glycerol plus dyes bromophenol blue and xylene cyanol) .
  • Example 4 In view of the binding to N. meninqitidis. alternate strategies were tested. These involved variations in the binding probe and the signal probe, with respect to size, and point of origin. The variations are presented infra, with “SDBP” referring to the binding probe, and “SDSP” to the signal probe. The first number refers to the length of the sequence, and the second number, its start relative to the 5'end of N. qonorrhoeae 16S rRNA gene.
  • Example 5 The observation described in Example 4, i.e., the importance of IBR length, was tested in subsequent experiments. In these, synthetic N. qonorrhoeae analytes were prepared, wherein single point mutations were incorporated. The SDBP-32-671/SDSP-25-678 complex was used, following the protocols given supra. Figure 2 shows that resolution down to a single base pair mismatch was possible. This is an advance over the current level of resolution in the art, and provides an opportunity, for the diagnosis of diseases caused by point mutations (e.g., sickle cell anemia) , as well as the differentiation of closely related organisms, including viruses.
  • point mutations e.g., sickle cell anemia
  • compositions were prepared based upon the sequence corresponding to bases 661-687 of N. qonorrhoeae. which, as indicated supra. differs from other Neisseria organisms at base 674. A number of complexes were prepared and were tested with controls, synthetic N. qonorrhoeae reagent, and with synthetic N. meninqitidis reagent.
  • the displacement assay involved use of 50 fmol of sample, and 10 fmol of hybrid complex. The materials were incubated at either 37°C or 50°C for one hour. The results of the displacement are shown in figures 3, 4, and 5. The results can be summarized, however, in the following Table 3:
  • Example 8 Stability of hybrids was studied in two different ways. The first approach preformed hybrid complex as described supra, which were stored at 4°C. Aliquots were then removed periodically, and assayed via gel electrophoresis. No dehybridization was found over a three week period. In a variation on this, the hybrid complexes were studied at 50°C, and less than 10% "dehybridization" was observed after 24 hours.
  • a second methodology for determining stability involved formation of the hybrids, evaporation to dryness, and storage at 4°C. Once a week, over a five week period, residues were redissolved in hybridization buffer, aliquots were removed, and gel electrophoresis was carried out. No dehybridization was observed even after five weeks.
  • Example 9 In these experiments rRNA from Neisseria was analyzed using hybrid complexes SDBP-32-671/SDSP-25-678 and SDBP- 24-671/SDSP-17-678. Both probes were 32 P labelled.
  • VRC vanadylribonucleoside complex
  • the precipitate was concentrated by centrifugation and resuspended in 300 ul of DEPC treated water. Optical densities were taken and the RNA was frozen in aliquots at -20°C. Homogeneity was checked by electrophoresing an 11.25 ul aliquot on 1% formaldehyde/agarose gel, followed by ethidium bromide visualization.
  • E. coli rRNA was a control. Average yields were 2.9 mg for N. qonorrhoeae, 2.7 mg for N. Meninqitidis, and 3.1 mg for N. lactamica. These samples contained both 16S and 23S rRNA, with the ratio being about 1/3:2/3. The protocols for hybridization as described supra were carried out.
  • Examples 1-9 show the feasibility of using the strand displacement assay discussed herein for identifying N. qonorrhoeae. The assay was also tested for identifying sickle cell anemia linked sequences.
  • Oligonucleotides were prepared in accordance with Bakloriti et al., Blood 74: 1817-1822 (1989) i.e.:
  • SCASP-1 5'-GAAGTCTGCCGTTACTG-3' (SEQ ID NO: 8) Signal Probe
  • SCABP-1 3'-GACTCCTCTTCAGACGGCAATGAC-5' (SEQ ID NO: 9)
  • SCABP-2 3'-GACACCTCTTCAGACGGCAATGAC-5' (SEQ ID NO: 10)
  • GGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTG-3' (SEQ ID NO: 11) (analyte, normal)
  • GGTGCACCTGACTCCTGTGGAGAAGTCTGCCGTTACTG-3' SEQ ID NO: 12 (analyte, disease)
  • Example 11 Examples 1-10 detail strand displacement assays which take place in solution.
  • a solid phase based assay system is most desirable, as the medical office and small laboratory, e.g., would find such systems quite desirable.
  • Latex beads with streptavidin coatings were used as the solid phase, it being noted that many methodologies for the attachment of this binder and the related molecule avidin are well known. These were used in connection with biotin labelled hybrid complexes. These complexes were the SDBP-32-671/ 32 P-SDSP-25-678 and the SDBP-32-1266/ 32 P-SDSP- 25-1273 materials described supra.
  • biotinylated probes and streptavidin beads were available, two different methodologies could be followed to carry out a strand displacement assay.
  • One format calls for carrying out the reaction between target analyte and hybrid complex, after which streptavidin labelled beads were added to collect any unreacted complex. Similarly, the complexes were preincubated with the beads, and strand displacement studied by adding the solid phase bound complex to the sample, and allowing strand displacement to proceed thereafter.
  • Figure 14 shows the results. In the control reaction, there was no analyte, and hybrid complex remains at the point of application. When correct analyte ("A" in the figure) is added, there is displacement, as is indicated by the gradual disappearance of radioactivity. This does not occur with N. meninqitidis ("M" in the figure) .
  • Example 13 Reaction kinetics were compared for systems where beads were added after displacement with the complex. All parameters were as in example 12. The results, presented in figures 15 and 16, show that when the beads were added with the complexes, 80% displacement occurred after 40 minutes. On the other hand, when beads were added later, 80% displacement occurred after only 10 minutes. In view of the marked difference in kinetics, subsequent experiments employ the faster reaction system.
  • Example 14
  • the strip based assays described supra used synthetic analyte. Feasibility of the assay using rRNA was tested.
  • the probe complex used was that of examples 11-13, and the analyte was either RNA extracted in the manner described supra. or synthetic analytes.
  • the protocols of the assay were those of examples 12 and 13. The results, as will be seen from figure 17, show that crude nucleic acid mixture (N. qonorrhoeae RR21) and pure RNA show displacement, whereas pure N. lactamica RNA and pure N. meninqitidis RNA did not.
  • Example 16 The probes represented by SEQ ID NOS: 4, 5 and 6, and their complements are useful in assays other than strand displacement assays. They were tested extensively, using over 200 clinical isolates of Neisseria qonorrhoeae, selected from around the world. To carry out the probe studies, 25 ul cultures of Neisseria strains were grown, and genomic DNA was extracted using standard methodologies. The DNA was purified, and checked on agarose for purity and integrity. Once this was done, 10 ug samples were applied to nylon membranes, again using standard technique. Probe samples were then added
  • RNA specificity In view of the results of Example 16, showing specificity for DNA, tests were carried out to test for RNA specificity. Twenty five strains of RNA were chosen at random, and RNA was extracted, either using standard methodologies or the methodology presented supra. Control strains were also used. Extracted RNA was quantitated and electrophoresed on 1% formaldehyde-agarose gels to ' check purity and integrity, after which 10 ug samples were applied to nylon membranes. The RNA was denatured by adding deionized formamide and formaldehyde incubated at 50°C for one hour, chilled on ice and then applied to
  • Probes 2A, 4 and 6 hybridized to the single stranded 16S rRNA whereas 1A, 3 and 5, which should be identical to the 16S rRNA, did not. The sensitivity in all three cases was 100%.
  • the method involves contacting a sample of interest with a hybrid complex.
  • the complex contains a binding probe, and a signal probe.
  • the first member of the complex may be divided into an initial binding region or "IBR", and target binding region.
  • the target binding region and signal probe are hybridized to each other, and the IBR extends out from the complex.
  • the whole of the binding probe must be complementary to the nucleic acid molecule to be assayed.
  • the complex is added to the sample and the binding probe begins to hybridize to the nucleic acid analyte of the sample. Hybrids of longer sequences are more stable than shorter ones, so hybridization between target and probe is favored, leading to displacement to the signal probe.
  • the signal probe is measured or observed, thereby providing a determination of the target analyte.
  • the binding probe the IBR must not be too long, so as to prevent hybridization to a non analyte sequence. This can happen with a binding probe if, for example, the IBR is 95% homologous to a non target sequence, and the 5% of difference is dispersed along the length of the IBR. When this happens, the IBR will in effect, ignore the random areas of non-complementarity and hybridize anyway. To avoid such problems, the IBR must be short enough to prevent non-complementary binding. Similarly, the entire probe sequence must be short enough to prevent formation of stable hybrids with non complementary sequences.
  • the entire probe sequence is only from 20 to 40 bases in length, a length of from 25 to 35 bases being particularly preferred.
  • the IBR is 10 or fewer bases in length, thus leaving a target binding region that is preferably 10 to 30 or even 15 to 35 nucleotide bases in length. Especially good results were found, e.g, with base lengths of 7 bases for the IBR, and 25 bases for the target binding region.
  • Hybrid complexes of the type described herein are useful for determining analytes, and can discriminate down to the level of a single base pair difference.
  • the complexes are useful in diagnostic assays for diverse analytes and pathological conditions, including point mutations.
  • diagnostic applications of the method are the determination of sexually transmitted diseases, virus infections, bacteria, chromosomal disorders, genetically inherited diseases, nucleic acid mutations, and so forth.
  • solution and solid phase assays may both be carried out, the latter category being particularly preferred.
  • assays where the hybrid complex is bound to a solid such as a bead or a nitrocellulose paper or nylon membrane, and the signal probe is displaced therefrom. The displaced signal may then be measured.
  • the binding probe may be bound to the solid phase in a number of ways known to the skilled artisan, as immobilization of nucleic acids to solid phases is somewhat routine.
  • Especially preferred systems immobilize the binding probe via a (strept) avidin- biotin binding system, where the elements of the binding system may be interchanged. Additional linker molecules may be used to bind the probe to the solid phase.
  • the signal probe is, of course, labelled to facilitate its identification.
  • Radiolabels such as 2 P and 35 S, etc. may be used, as may any of the many signals used to label nucleic acid sequences.
  • Metal particles such as gold sols, may be used, as may fluorescent, chemiluminescent, or other materials which present an "inherent" signal, such as colored microparticles.
  • Other labels may also be used which are not inherently signal producers in that they require further treatment to be detected.
  • Such materials include enzymes, such as the peroxidases and alkaline phosphatases, where a substrate for the enzyme is added to provide a signal, magnetic particles, antigenic or haptenic molecules, antibodies, and so forth, where a further reaction is required to indicate the signal's presence.
  • the invention also includes reagent kits and complexes useful in carrying out displacement assays of the type described herein.
  • inventive complexes are those described supra.
  • Reagent kits include the complex, and may include, e.g., a solid phase component for subsequent binding of the complex either before or after running the assay, and a signal means for detecting the label on the signal probe.
  • the signal means is kept separate from the labeled sequence, while the solid phase material may or may not be directly bound to the binding probe. It is also possible, if desired, to present the binding probe and signal probe in separate portions of the kit.
  • the attachment of the complex to solid phases also allows the artisan to prepare diagnostic apparatus, where a solid carrier support, such as a nitrocellulose paper strip, has complex immobilized thereon.
  • the strip may include at a point downstream of the attached complex a signal generating system for determining displaced label.
  • the signal generating system may also be presented "off board" of the strip in the form, e.g., of a container of reagent.
  • the first few examples of this application also set forth isolated nucleic acid sequence which are useful as specific N. gonorrhoea diagnostic probes. These oligomer ⁇ do not hybridize with other species of Neisseria to a degree leading to false positives, thereby making them especially useful in diagnosing gonorrhea. SEQ ID NOS: 1, 4-6, and 7, e.g., are examples of such oligomers.
  • probes may be labelled in any of the ways described supra, as well as all other ways known to the art.
  • Different assay formats can be used in conjunction with the strand displacement assay as described.
  • One particularly desirable application of the assay is in an automated system.
  • hybrid complex is immobilized on a solid phase, such as the inner wall of a test tube or reaction cuvette.
  • the complex can be immobilized directly, via a (strept) avidin-biotin complex, or any of the other means available to the artisan for immobilization of nucleic acids.
  • Sample is then added to the carrier of the complex, resulting in displacement of signal probe to sample liquid, supernatant, etc.
  • the signal probe containing liquid may then be transferred to some point within the automated system where it is measured.
  • Other aspects of the invention will also be clear to the skilled artisan, and need not be repeated here.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP93921591A 1992-09-15 1993-09-15 Isolierte nukleotid-sequenzen zum nachweis von neisseria gonorrhoeae Expired - Lifetime EP0660844B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US945159 1992-09-15
US07/945,159 US5389515A (en) 1992-09-15 1992-09-15 Isolated nucleotide sequences for identifying Neisseria gonorrhoeae
PCT/US1993/008702 WO1994006817A1 (en) 1992-09-15 1993-09-15 Isolated nucleotide sequences for identifying neisseria gonorrhoeae

Publications (3)

Publication Number Publication Date
EP0660844A1 true EP0660844A1 (de) 1995-07-05
EP0660844A4 EP0660844A4 (de) 1997-05-21
EP0660844B1 EP0660844B1 (de) 2001-07-18

Family

ID=25482727

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93921591A Expired - Lifetime EP0660844B1 (de) 1992-09-15 1993-09-15 Isolierte nukleotid-sequenzen zum nachweis von neisseria gonorrhoeae

Country Status (6)

Country Link
US (1) US5389515A (de)
EP (1) EP0660844B1 (de)
JP (1) JPH08501220A (de)
DE (1) DE69330463T2 (de)
ES (1) ES2161230T3 (de)
WO (1) WO1994006817A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994068A (en) * 1997-03-11 1999-11-30 Wisconsin Alumni Research Foundation Nucleic acid indexing
US5962273A (en) * 1997-11-04 1999-10-05 Becton Dickinson And Company Detection of Neisseria gonorrhoeae by amplification and detection of its nucleic acid
US6080543A (en) * 1997-12-08 2000-06-27 E. & J. Gallo Winery Detection of fungal pathogens
US6248519B1 (en) 1998-03-11 2001-06-19 E & J Gallo Winery Detection of fermentation-related microorganisms
US5976805A (en) * 1998-04-27 1999-11-02 Becton Dickinson And Company Neisseria gonorrhoeae specific DNA fragment--GC3
US6287779B1 (en) 2000-01-20 2001-09-11 E. & J. Gallo Winery Detection of fermentation-related microorganisms
US6696524B2 (en) 2001-02-20 2004-02-24 E. I. Du Pont De Nemours And Company Low Tg ethylene-based polymer, cycloolefin polymer blends
KR100532665B1 (ko) * 2002-11-28 2005-12-02 주식회사 바이오메드랩 나이세리아속 균 탐지용 프로브, 이를 이용한나이세리아속 균의 유전형 분석키트 및 유전형 분석방법
WO2004094986A2 (en) * 2003-04-16 2004-11-04 Handylab, Inc. System and method for electrochemical detection of biological compounds
EP1697541B1 (de) * 2003-12-19 2013-03-20 Roche Diagnostics GmbH Oligonukleotide, Verfahren und Kits zum Nachweis von Neisseria Gonorrhoeae
US7229800B2 (en) * 2004-04-16 2007-06-12 Becton, Dickinson And Company Neisseria gonorrhoeae assay
US7842794B2 (en) 2004-12-17 2010-11-30 Roche Molecular Systems, Inc. Reagents and methods for detecting Neisseria gonorrhoeae
US8329884B2 (en) 2004-12-17 2012-12-11 Roche Molecular Systems, Inc. Reagents and methods for detecting Neisseria gonorrhoeae

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003227A1 (en) * 1984-11-23 1986-06-05 Dgi, Inc. An assay for nucleic acid sequences, particularly genetic lesions
EP0281927A2 (de) * 1987-03-11 1988-09-14 Bayer Corporation Verfahren zum Nachweis einer Nukleinsäure-Sequenz in einer Probe
EP0505012A2 (de) * 1985-03-28 1992-09-23 F. Hoffmann-La Roche Ag Mittel zur Amplifizierung von Nukleinsäuresequenzen
WO1993002216A1 (en) * 1991-07-19 1993-02-04 Upstate Biotechnology, Inc. Method for detection of mutations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446230A (en) * 1981-10-30 1984-05-01 Temple University Of The Commonwealth System Of Higher Education Test method for the laboratory diagnosis of Gonorrhea and test strain of neisseria gonorrhoeae
GB8527687D0 (en) * 1985-11-09 1985-12-11 Wales University Of College Of Silver intensification of diaminobenzidine
US4900659A (en) * 1986-01-30 1990-02-13 Enzo Biochem, Inc. Nucleotide sequence composition and method for detection of Neisseria gonorrhoeae and method for screening for a nucleotide sequence that is specific for a genetically distinct group
AU616646B2 (en) * 1986-11-24 1991-11-07 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US4905379A (en) * 1987-02-13 1990-03-06 Beloit Corporation Intermediate vacuum roll for dryer
EP0337896B1 (de) * 1988-04-15 1993-07-28 N.V. Innogenetics S.A. Hybridisationssonden zum Nachweis von Neisseria-Stämme
US5099011A (en) * 1988-08-02 1992-03-24 Ortho Diagnostic Systems Inc. Nucleic acid probe for detection of Neisseria gonorrhoea
US5047523A (en) * 1988-08-02 1991-09-10 Ortho Diagnostic Systems Inc. Nucleic acid probe for detection of neisseria gonorrhoea
AU5966990A (en) * 1989-05-24 1990-12-18 Gene-Trak Systems Nucleic acid probes for the detection of neisseria gonorrhoeae
DE3923341A1 (de) * 1989-07-14 1991-01-24 Boehringer Mannheim Gmbh Neisseria gonorrhoeae-nachweis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003227A1 (en) * 1984-11-23 1986-06-05 Dgi, Inc. An assay for nucleic acid sequences, particularly genetic lesions
EP0505012A2 (de) * 1985-03-28 1992-09-23 F. Hoffmann-La Roche Ag Mittel zur Amplifizierung von Nukleinsäuresequenzen
EP0281927A2 (de) * 1987-03-11 1988-09-14 Bayer Corporation Verfahren zum Nachweis einer Nukleinsäure-Sequenz in einer Probe
WO1993002216A1 (en) * 1991-07-19 1993-02-04 Upstate Biotechnology, Inc. Method for detection of mutations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
INT.SYST.BACTERIOL., vol. 44, 1994, pages 387-391, XP000605280 ENRIGHT ET AL.: "Phylogenetic relationships between some members of the genera Neisseria, Acinetobacter, Moraxella and Kingella based on partial 16S ribosomal DNA sequence and analysis." *
PROC.NATL.ACAD.SCI., vol. 80, January 1983, USA, pages 278-282, XP002026703 CONNER ET AL.: "Detection of sickle cell b(s)-globin allele by hybridization with synthetic oligonucleotides" *
See also references of WO9406817A1 *
THE LANCET, 12 January 1985, pages 75-77, XP002026704 RUBIN AND KAN: "A simple sensitive prenatal test for hydrops fetalis caused by a-thalassaemia" *

Also Published As

Publication number Publication date
DE69330463D1 (de) 2001-08-23
US5389515A (en) 1995-02-14
DE69330463T2 (de) 2001-12-13
EP0660844B1 (de) 2001-07-18
ES2161230T3 (es) 2001-12-01
JPH08501220A (ja) 1996-02-13
WO1994006817A1 (en) 1994-03-31
EP0660844A4 (de) 1997-05-21

Similar Documents

Publication Publication Date Title
US5445933A (en) Strand displacement assay and complex useful therefor
AU599083B2 (en) Detection of microorganisms in a nucleic acid containing sample
JP5166666B2 (ja) 型特異的ハイブリッド捕捉法による核酸の検出方法
EP0875583B1 (de) Primer und Kit für den Nachweis von Chlamydia trachomatis
US5580971A (en) Fungal detection system based on rRNA probes
EP0557456A1 (de) Nichtisotopischer nachweis von nukleinsäuren mittels eines "sandwich"-hybridisierungtestverfahrens unter verwendung eines polystyrolträgers und zusammensetzungen dafür
JPH0364119B2 (de)
EP0660844B1 (de) Isolierte nukleotid-sequenzen zum nachweis von neisseria gonorrhoeae
EP0795033A2 (de) Entwurf diskontinuierlicher sonden unter verwendung von hybritopemapping
US5780227A (en) Oligonucleotide probe conjugated to a purified hydrophilic alkaline phosphatase and uses thereof
CA2070632A1 (en) Use of dna-dependent rna polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays
JPH04504058A (ja) 親和性捕捉法の妨害の防止
JP2547517B2 (ja) 鳥型結核菌、ミコバクテリウム・イントラセルレアおよびパラ結核菌に対するプローブ
EP0128018A2 (de) Molekulare genetische Sonde und Verfahren zu ihrer Herstellung, Testmethode und Satz in denen diese molekulare genetische Sonde gebraucht wird
US20010039012A1 (en) Methods for diagnostic screening
JPH01501339A (ja) 改良された核酸ハイブリダイゼーション方法及びそれに用いるキット
JP4986367B2 (ja) イン・サイチュー解析のためのオリゴヌクレオチドプローブおよびタンパク質を標識するためのオリゴヌクレオチド配列式
WO1988006189A1 (en) Test system, test device and method for detecting pathogenic organisms and antibiotic resistance genes in body fluids
WO1997044488A2 (en) Compositions and methods for the detection of mycobacterium kansasii
EP0422873B1 (de) Nukleinsäure-Sonden und Verfahren zum Nachweis von Cryptococcus Neoformans
JP2651317B2 (ja) 核酸の検出法
US20030219755A1 (en) Compositions and methods for performing hybridization assays using target enhanced signal amplification (TESA)
WO2000011215A2 (en) Method for diagnostic screening
JP2004514437A (ja) ネグレリア属の原虫を検出する方法
Kolman Molecular Anthropology: Progress and Perspectives on Ancient DNA Technology

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950418

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE ES FR GB IT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROCHE DIAGNOSTICS CORPORATION

17Q First examination report despatched

Effective date: 19990809

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE ES FR GB IT

REF Corresponds to:

Ref document number: 69330463

Country of ref document: DE

Date of ref document: 20010823

ITF It: translation for a ep patent filed
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2161230

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20120829

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120910

Year of fee payment: 20

Ref country code: IT

Payment date: 20120921

Year of fee payment: 20

Ref country code: ES

Payment date: 20120911

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20120928

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69330463

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20130914

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130917

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130914

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130916